Three methods for quantifying skeletal alkaline phosphatase (ALP; EC 3.1.3.1) activity/immunoactivity in serumheat inactivation, wheat germ agglutinin (WGA) precipitation, and an immunoradiometric assay-were tested for recovery and specificity and applied to 81 sera collected from 14 postmenopausal osteoporotic subjects. The heatinactivation and WGA precipitation assays showed relative recoveries of 91-100% and 16-32%, respectively, for skeletal ALP with complete specificity (no cross-reactivity with hepatic or intestinal ALP); the IRMA showed a relafive recovery of 86-100% and 11-14% cross-reactivity with hepatic ALP. There was a closer correlation between the heat-inactivation assay and IRMA (r = 0.833) than between the WGA precipitation assay and IRMA (r 0.673) or between the heat-inactivation and WGA-precipitation assays (r = 0.568). The WGA precipitation assay failed to detect skeletal ALP in three serum samples that contained significant amounts as determined by the heatinactivation assay and the IRMA.
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Indexing Terms: osteoporosis/bone formation/Iect!ns/glycosylation/isoenzymes
Skeletalalkalinephosphatase (ALP; EC 3.1.3.1), an ectoenzyme of osteoblasts, is released to the circulation by phosphatidylinositol glycanase activityand (or)formation of membrane vesicles(1-9 )6 Previous in vitro studies have shown that the amount of skeletalALP activity in osteoblast-ilne cellsand in bones is proportionalto collagen formation (10, 11), and previous clinical studies have shown that the amount ofskeletal ALP activityin serum can provide an index of the rate of bone formation (12) (13) (14) .
However, because human serum contains a variable mixture of ALP isoenzymes from liver, intestine, and bone (and, during pregnancy, from the placenta), measurement of skeletalALP in serum requires isoenzyme separation.
Although sepa- (53) and serum samples from osteoporotic subjects. Our goal was to identifyone or more assay methods that could be used to identify skeletal ALP in osteoporotic serum, with the presumption that this would provide an index of the rate of bone formation (12) (13) (14) . 
MaterIals and Methods

Serum Samples
Procter
and Gamble Pharmaceuticals (Cincinnati, OH) supplied 81 sera that had been obtained (with informed consent) from osteoporotic subjects during the course of two previous studies. The sera represented serial samples obtained from 14 postmenopausal osteoporotic subjects over 3 years, during which time two of the subjects had been treated with etidronate, four with phosphate and etidronate, two with phosphate and placebo, and three with placebo. Three additional samples were obtained from patients receiving estrogen. Because the current studies were intended only to compare the three assay methods for quantification of skeletal ALP in serum, we did not assess the effects of time or treatment.
The frozen sera (0.7-1.0 mL4/sample) were sent to Loma Linda, CA, where they were thawed and divided into aliquots: 0.15 mL for the heat-inactivation assay; 0.225 mL for the WGA precipitation assay; and the remainder (0.3-0.55 mL) for the IRMA. All of the aliquots were then refrozen and the samples for immunoassay were directly transferred (frozen) to Hybritech. (11, 26, 53, 54) .
Increases in absorbance at 410 nm during incubation at 22#{176}C for 3-30 mm (corresponding to the time-dependent increase in p-mtrophenol concentration)
were measured with a microtiter plate spectrophotometer (Model EAR 400 AT; SLT Lab Instruments, Hilisborough, NC). All assays were performed in duplicate. ALP activities are reported as U/L, where 1 U = 1 unol of PNPP hydrolyzed per minute at room temperatore (22 ± 1#{176}C); we used 6.0 L mmol' cm as the absorbtivity of p-nitrophenol at 410 nm, a value determined by experiment and applicable specifically to our reaction protocoL Because the incubation time can be varied between 3 mm and 3 h, this assay method has a theoretical range for total serum ALP activity of 1500- Use of these calibrators assumes that, for subjects with Paget disease and total serum ALP activities >1500 UIL, total serum ALP = skeletal ALP (1).
(b) As in previous studies (53, 54) , skeletal ALP activity was prepared from SaOS-2 cells (55, 56) by n-butanol extraction and diluted into HIS to yield a final activity of 100.3 UIL.
Hepatic ALP activity. As in previous studies (26, 54), cholestatic sera (obtained with consent) were diluted into HIS to yield final activities of 140.5 and 118.2 UIL. Use of these calibrators assumes that, for subjects with cholestasis and total serum ALP activities of 440 and 618 UIL, total serum ALP = hepatic ALP (1, 53).
Intestinal ALP activity. As in previous studies (25,26, 53), intestinal ALP activity was prepared by n-butanol extraction of human duodenum/jejunum (obtained at autopsy) and diluted into HIS to yield a final activity of 40.7 U/L.
Quantification of skeletal ALP isoenzyme activity
By heat inactivation.
As in previous studies ( 0.10 mL of serum and 0.10 mL of acetate buffer (without WGA), were used to measure total serum ALP activity. Aliquots of the calibrators for skeletal, hepatic, and intestinal ALP isoenzymes that were used in the heat-inactivation assay were also included in these assays, as were negative controls containing HIS without added ALP, and the kit calibration control (lyophilized serum serving as internal standard). ALP activities were determined as described above in a total volume of 0.3 mL, containing 10 mmol/L PNPP, 1 mmol/L MgC12, and enzyme, in 0. 15 
Statistical Analysis
NCSS statistical software (NCSS, Kaysville, UT) was used to evaluate the data and compare the results of the three assay methods by linear regression analyses.
Results
Comparisons
of isoenzyme assay recovery and specificity. We compared heat inactivation, WGA precipitation, and IRMA for quantitation of skeletal ALP with respect We also compared the assays with respect to specificity for skeletal ALP by testing for cross-reactivity with calibrators of ALP isoenzymes prepared from human intestine (intestinal ALP) or hepatic serum (hepatic ALP). Because these calibrators were prepared by dilution into HIS (i.e., heated serum without measurable ALP activity), we also included HIS as a negative control. As summarized in 
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Cross-reactivitles for theheat inactivationand WGA assays were calculated as the percentage of total ALP activity identified as skeletalALP.
Calculated (and relative) cross-reactivitles for the IRMA were calculated as descnbed in footnotes to Table 1 Table 4 . As anticipated, the correlation between total serum ALP activity as determined by the heat-inactivation and WGA precipitation assays was close (r = 0.89).
[This correlation could have been increased to r = 0.94 by omitting the data from one serum sample that gave bAJI correlations were significant at P < 0.0001 (n = 79 or 80).
the two pagetic serum calibrators as skeletal. Given that these sera were obtained from patients with active Paget disease and total serum ALP activities 780 and 360 times the upper limit of normal, we cannot dismiss the possibilities that (a) the WGA precipitation assay is sensitive to HIS dilution, and (or) (b) the amount of skeletal ALP activity in the less-diluted pagetic calibrator may have been outside the linear range of the WGA precipitation assay. Regarding the latter concern, the instructions that came with the WGA kit indicated that the WGA precipitation assay could be applied to any ALP sample that could be measured colorimetrically, and with our methodology, reflected an upper limit of -1500 U/L.-i.e., an absorbance change of 1.125 A during a 3-min incubation at 22#{176}C-well above the measured value of 189 U/L for skeletal ALP. Furthermore, this would not explain the poor apparent recovery of skeletal ALP activity from the diluted pagetic calibrator.
Regarding the possibility of dilution-dependent errors, our previous data suggested that neither WGA precipitation nor concanavalin A precipitation was acutely sensitive to changes in the concentration of serum (53) . The current studies also showed that the WGA precipitation assay identified as skeletal only 9.7% of the ALP activity in the skeletal ALP calibrator that had Because WGA precipitation is dependent on binding to glycosyl moieties (particularly sialic acid residues), these apparent differences in skeletal ALP recovery are probably indicative of differences in ALP glycosylation. Previous studies have shown that skeletal ALP activity in serum is heterogeneous with respect to carbohydrate moieties (58) , and that the spectrum of skeletal ALP glycoforms may differ with age and (or) metabolic status (58, 59 The IRMA systematically identified more skeletal ALP in the osteoporotic sera than did either the heatinactivation or the WGA precipitation assays (50% and 29% more, respectively). Although this discrepancy could reflect either an inequality between immunological units and enzyme activity units (1 U = 1.3-1.5113) or a lack of specificity (e.g., cross-reactivity with hepatic ALP), our observations suggest that the latter explanation is more likely. The data summarized in Table 1 Table 2 show that the IRMA had an absolute cross-reactivity of 8.7-10.5% (11.4-13.8% relative to the sensitivity to the dilute pagetic serum calibrator); if we assume that the mean concentration of hepatic ALP in the osteoporotic sera was -47 U/L (i.e., 71 UIL total ALP -24 U/L skeletal ALP), we might expect the IRMA to overestimate the skeletal ALP by [5] [6] .5 U/b, or 21-27%. Additional studies will be required to resolve this issue. 
